
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<html><head>
<meta http-equiv="content-type" content="text/html; charset=windows-1252">
<title>Xapian_query_results_NEAR</title>
</head>
<body>

<table border="1" width="100%">
  <tbody><tr>
    <th>Rank</th>
    <th>PubMed-ID</th>
    <th>Title (query term highlighted)</th>
  </tr>
<tr><td>0</td><td>16317266</td><td><b>Erlotinib</b> and chemoradiation followed by maintenance <b>erlotinib</b> for locally advanced <b>pancreatic</b> <b>cancer</b>: a phase I study.</td></tr><tr><td>1</td><td>17878488</td><td><b>Erlotinib</b> in <b>pancreatic</b> <b>cancer</b> patients: do we need more information from the NCIC CTG trial?</td></tr><tr><td>2</td><td>17906218</td><td>Does a statistically significant survival benefit of <b>erlotinib</b> plus gemcitabine for advanced <b>pancreatic</b> <b>cancer</b> translate into clinical significance and value?</td></tr><tr><td>3</td><td>18089885</td><td><b>Erlotinib</b> in <b>pancreatic</b> <b>cancer</b>: are tumor cells the (only) target?</td></tr><tr><td>4</td><td>18615326</td><td>Irreversible ototoxicity associated with the use of <b>erlotinib</b> in a patient with <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>5</td><td>18360654</td><td>Role of <b>erlotinib</b> in the management of <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>6</td><td>17704662</td><td>Severe lung and skin toxicity during treatment with gemcitabine and <b>erlotinib</b> for metastatic <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>7</td><td>20868602</td><td>[Efficacy of gemcitabine combined with <b>erlotinib</b> in patients with advanced <b>pancreatic</b> <b>cancer</b>].</td></tr><tr><td>8</td><td>17935272</td><td>Tyrosine kinase inhibitors in non-small cell lung and <b>pancreatic</b> <b>cancer</b>: the emerging role of <b>erlotinib</b>.</td></tr><tr><td>9</td><td>23378339</td><td><b>Erlotinib</b> prolongs survival in <b>pancreatic</b> <b>cancer</b> by blocking gemcitabine-induced MAPK signals.</td></tr><tr><td>10</td><td>20107864</td><td>A phase II study of isoflavones, <b>erlotinib</b>, and gemcitabine in advanced <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>11</td><td>22272248</td><td>Phase I evaluation of intravenous ascorbic acid in combination with gemcitabine and <b>erlotinib</b> in patients with metastatic <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>12</td><td>20927525</td><td>Phase II study of a fixed dose-rate infusion of gemcitabine associated with <b>erlotinib</b> in advanced <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>13</td><td>23435671</td><td>KRAS mutation status is not predictive for objective response to anti-EGFR treatment with <b>erlotinib</b> in patients with advanced <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>14</td><td>24413779</td><td>Management of advanced <b>pancreatic</b> <b>cancer</b> with gemcitabine plus <b>erlotinib</b>: efficacy and safety results in clinical practice.</td></tr><tr><td>15</td><td>25145842</td><td>Response to GEMOX plus <b>erlotinib</b> in <b>pancreatic</b> <b>cancer</b> is associated with ERCC1 overexpression.</td></tr><tr><td>16</td><td>23235319</td><td>Phase I trial of gemcitabine combined with capecitabine and <b>erlotinib</b> in advanced <b>pancreatic</b> <b>cancer</b>: a clinical and pharmacological study.</td></tr><tr><td>17</td><td>17947726</td><td>Capecitabine plus <b>erlotinib</b> in gemcitabine-refractory advanced <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>18</td><td>25247318</td><td>Dose escalation to rash for <b>erlotinib</b> plus gemcitabine for metastatic <b>pancreatic</b> <b>cancer</b>: the phase II RACHEL study.</td></tr><tr><td>19</td><td>25864651</td><td>Amiloride sensitizes human <b>pancreatic</b> <b>cancer</b> cells to <b>erlotinib</b> in vitro through inhibition of the PI3KAKT signaling pathway.</td></tr><tr><td>20</td><td>24857345</td><td>A phase II study of <b>erlotinib</b> in gemcitabine refractory advanced <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>21</td><td>24574334</td><td>Phase II trial of sorafenib and <b>erlotinib</b> in advanced <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>22</td><td>20130876</td><td>A phase II study of bevacizumab plus <b>erlotinib</b> for gemcitabine-refractory metastatic <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>23</td><td>19307500</td><td>Phase III trial of bevacizumab in combination with gemcitabine and <b>erlotinib</b> in patients with metastatic <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>24</td><td>22614154</td><td>Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with <b>erlotinib</b> (GE) in unresectable <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>25</td><td>22699203</td><td>The association of rash severity with overall survival: findings from patients receiving <b>erlotinib</b> for <b>pancreatic</b> <b>cancer</b> in the community setting.</td></tr><tr><td>26</td><td>25688740</td><td>Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of <b>erlotinib</b> in <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>27</td><td>21549514</td><td>Phase I study of conformal radiotherapy and concurrent full-dose gemcitabine with <b>erlotinib</b> for unresected <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>28</td><td>17457047</td><td>ErbB3 expression and dimerization with EGFR influence <b>pancreatic</b> <b>cancer</b> cell sensitivity to <b>erlotinib</b>.</td></tr><tr><td>29</td><td>25164437</td><td>pERK, pAKT and p53 as tissue biomarkers in <b>erlotinib</b>-treated patients with advanced <b>pancreatic</b> <b>cancer</b>: a translational subgroup analysis from AIO-PK0104.</td></tr><tr><td>30</td><td>17079479</td><td>Potentiation of the effect of <b>erlotinib</b> by genistein in <b>pancreatic</b> <b>cancer</b>: the role of Akt and nuclear factor-kappaB.</td></tr><tr><td>31</td><td>18803351</td><td>Anti-tumor activity of <b>erlotinib</b> in the BxPC-3 <b>pancreatic</b> <b>cancer</b> cell line.</td></tr><tr><td>32</td><td>23472089</td><td>Gemcitabine plus <b>erlotinib</b> for advanced <b>pancreatic</b> <b>cancer</b>: a systematic review with meta-analysis.</td></tr><tr><td>33</td><td>23169292</td><td>EGFR pathway biomarkers in <b>erlotinib</b>-treated patients with advanced <b>pancreatic</b> <b>cancer</b>: translational results from the randomised, crossover phase 3 trial AIO-PK0104.</td></tr><tr><td>34</td><td>23180942</td><td>Insights into <b>erlotinib</b> action in <b>pancreatic</b> <b>cancer</b> cells using a combined experimental and mathematical approach.</td></tr><tr><td>35</td><td>25503169</td><td>Radiation recall gastritis secondary to <b>erlotinib</b> in a patient with <b>pancreatic</b> <b>cancer</b>.</td></tr><tr><td>36</td><td>22593509</td><td>Combination therapy with gemcitabine (GEM) and <b>erlotinib</b> (E) in exocrine <b>pancreatic</b> <b>cancer</b> under special reference to RASH and the tumour marker CA19-9.</td></tr><tr><td>37</td><td>19858399</td><td>Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus <b>erlotinib</b> in advanced <b>pancreatic</b> <b>cancer</b>.</td></tr>
</tbody></table>

</body></html>
